Lisa Nodzon
Nurse Practitioner · Tampa, FLNPI 1942591854
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AstraZeneca at 34.8% of the total. Reporting peaked in 2022 at $77,008 and has fallen 77.9% since, to $16,986 in 2025. Among nurse practitioner clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $702.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$86K
- AbbVie$61K
- Genentech USA, Inc.$37K
- Pharmacyclics LLC, An Abbvie Company$29K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- Adaptive Biotechnologies Corporation$12K
- plus $9K from 17 others
What the payments were for
- Consulting fees$67,45727%
- Speaking & faculty fees$139,18057%
- Travel & lodging$29,46012%
- Food & beverage$9,6074%
- Education$2530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $85,706 |
| AbbVie | 83 | $60,956 |
| Genentech USA, Inc. | 40 | $36,753 |
| Pharmacyclics LLC, An Abbvie Company | 57 | $28,838 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $13,003 |
| Adaptive Biotechnologies Corporation | 13 | $11,689 |
| Novartis | 3 | $2,360 |
| Beigene USA, Inc. | 2 | $1,950 |
| Agios Pharmaceuticals, Inc. | 2 | $1,240 |
| Johnson & Johnson | 8 | $1,062 |
| Rigel Pharmaceuticals, Inc. | 11 | $947 |
| Blueprint Medicines Corporation | 2 | $215 |
| TG Therapeutics, Inc. | 2 | $215 |
| Genmab U.S., Inc. | 3 | $171 |
| Bristol Myers Squibb | 1 | $131 |
| Fresenius Kabi USA, LLC | 1 | $126 |
| Deciphera Pharmaceuticals Inc. | 1 | $125 |
| Cycle Pharmaceuticals Inc | 1 | $114 |
| Genetix Biotherapeutics Inc | 2 | $84 |
| Lilly USA, LLC | 1 | $84 |
| Menarini Silicon Biosystems, Inc. | 1 | $83 |
| Incyte Corporation | 1 | $74 |
| Aadi Bioscience, Inc. | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$245,957 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 109 | $1,480,340 |
| CalquenceAcalabrutinib Maleate | 102 | $1,457,009 |
| BosulifBosutinib | 33 | $570,680 |
| BrukinsaZanubrutinib | 34 | $389,823 |
| VenclextaVenetoclax | 24 | $342,386 |
| TasignaNilotinib Hcl | 35 | $301,863 |
| SprycelDasatinib | 17 | $137,650 |
| Acyclovir | 64 | $1,467 |
| Allopurinol | 38 | $360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $28,838 | $1,480,340109 claims |
| AstraZenecaCalquence | $85,706 | $1,457,009102 claims |
| Beigene USA, Inc.Brukinsa | $1,950 | $389,82334 claims |
| AbbVieVenclexta | $60,956 | $342,38624 claims |
| NovartisTasigna | $2,360 | $301,86335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Tampa
- April WessonTampa$342K
- Ashima BahlTampa$226K
- Jennifer PuleoTampa$171K
- Melissa CarverTampa$129K
- Jerrica FariasTampa$127K
- Sara TinsleyTampa$93K
- Erin ParkinsonTampa$65K
- Michele LaineTampa$58K
- Jana BucknerTampa$58K
- Tiffany TrentTampa$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.